Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of “Buy” by Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.57.

Several equities research analysts have commented on AQST shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Monday, March 10th. Lake Street Capital dropped their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $3.02 on Monday. The stock’s 50-day moving average is $2.99 and its 200 day moving average is $3.94. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $5.80. The company has a market cap of $298.59 million, a P/E ratio of -6.71 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. On average, analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $90,000. Charles Schwab Investment Management Inc. boosted its position in shares of Aquestive Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after buying an additional 9,268 shares during the period. Quantbot Technologies LP purchased a new position in shares of Aquestive Therapeutics during the third quarter worth $135,000. BNP Paribas Financial Markets boosted its position in Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after buying an additional 13,481 shares during the period. Finally, MetLife Investment Management LLC increased its holdings in Aquestive Therapeutics by 86.3% in the third quarter. MetLife Investment Management LLC now owns 36,096 shares of the company’s stock valued at $180,000 after buying an additional 16,716 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.